Interferon therapy in hepatitis C

N. N. Zein, Jorge Rakela

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Interferon is effective for the treatment of hepatitis C infection in some patients. Although its effectiveness is established in patients with chronic hepatitis C infection, more work need to be done before it can be recommended for the treatment of patients with acute HCV infection. The currently recommended therapeutic regimen is 3 MU three times weekly, but higher dosages and longer duration of therapy may be more beneficial. Multiple factors including the degree of inflammation and fibrosis, HCV-RNA titer, and HCV genotype may influence the response to therapy. Therefore proper patient selection will improve response rate, and make interferon treatment more cost-effective. No controlled studies have yet evaluated the use of interferon in children with chronic HCV infection. Many questions are yet to be answered regarding interferon therapy in patients with chronic hepatitis C, thus we recommend all patients who belong to these categories be enrolled in clinical trials.

Original languageEnglish (US)
Pages (from-to)46-53
Number of pages8
JournalSeminars in Gastrointestinal Disease
Volume6
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

Hepatitis C
Interferons
Chronic Hepatitis C
Infection
Therapeutics
Health Care Costs
Patient Selection
Fibrosis
Genotype
Clinical Trials
RNA
Inflammation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Interferon therapy in hepatitis C. / Zein, N. N.; Rakela, Jorge.

In: Seminars in Gastrointestinal Disease, Vol. 6, No. 1, 1995, p. 46-53.

Research output: Contribution to journalArticle

@article{4396c505866f4fb58fdd2c8ffc4f9f62,
title = "Interferon therapy in hepatitis C",
abstract = "Interferon is effective for the treatment of hepatitis C infection in some patients. Although its effectiveness is established in patients with chronic hepatitis C infection, more work need to be done before it can be recommended for the treatment of patients with acute HCV infection. The currently recommended therapeutic regimen is 3 MU three times weekly, but higher dosages and longer duration of therapy may be more beneficial. Multiple factors including the degree of inflammation and fibrosis, HCV-RNA titer, and HCV genotype may influence the response to therapy. Therefore proper patient selection will improve response rate, and make interferon treatment more cost-effective. No controlled studies have yet evaluated the use of interferon in children with chronic HCV infection. Many questions are yet to be answered regarding interferon therapy in patients with chronic hepatitis C, thus we recommend all patients who belong to these categories be enrolled in clinical trials.",
author = "Zein, {N. N.} and Jorge Rakela",
year = "1995",
language = "English (US)",
volume = "6",
pages = "46--53",
journal = "Seminars in Gastrointestinal Disease",
issn = "1049-5118",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Interferon therapy in hepatitis C

AU - Zein, N. N.

AU - Rakela, Jorge

PY - 1995

Y1 - 1995

N2 - Interferon is effective for the treatment of hepatitis C infection in some patients. Although its effectiveness is established in patients with chronic hepatitis C infection, more work need to be done before it can be recommended for the treatment of patients with acute HCV infection. The currently recommended therapeutic regimen is 3 MU three times weekly, but higher dosages and longer duration of therapy may be more beneficial. Multiple factors including the degree of inflammation and fibrosis, HCV-RNA titer, and HCV genotype may influence the response to therapy. Therefore proper patient selection will improve response rate, and make interferon treatment more cost-effective. No controlled studies have yet evaluated the use of interferon in children with chronic HCV infection. Many questions are yet to be answered regarding interferon therapy in patients with chronic hepatitis C, thus we recommend all patients who belong to these categories be enrolled in clinical trials.

AB - Interferon is effective for the treatment of hepatitis C infection in some patients. Although its effectiveness is established in patients with chronic hepatitis C infection, more work need to be done before it can be recommended for the treatment of patients with acute HCV infection. The currently recommended therapeutic regimen is 3 MU three times weekly, but higher dosages and longer duration of therapy may be more beneficial. Multiple factors including the degree of inflammation and fibrosis, HCV-RNA titer, and HCV genotype may influence the response to therapy. Therefore proper patient selection will improve response rate, and make interferon treatment more cost-effective. No controlled studies have yet evaluated the use of interferon in children with chronic HCV infection. Many questions are yet to be answered regarding interferon therapy in patients with chronic hepatitis C, thus we recommend all patients who belong to these categories be enrolled in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0028812022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028812022&partnerID=8YFLogxK

M3 - Article

C2 - 7894967

AN - SCOPUS:0028812022

VL - 6

SP - 46

EP - 53

JO - Seminars in Gastrointestinal Disease

JF - Seminars in Gastrointestinal Disease

SN - 1049-5118

IS - 1

ER -